Policy The finding, achieved with weekly injections of the GLP-1 receptor agonist semaglutide (Wegovy, Ozempic) in the multicenter SELECT trial, establishes overweight/obesity as a modifiable risk factor for CVD, according to lead investigator A
Studies show that many users achieve significant weight reduction
Avoid injecting into skin that is red, bruised, tender, hard, scarred, or irritated
It helps protect cells from oxidative stress
They Dont Require a Prescription 2
What should I tell my knee surgeon if I am already using peptides